In France, more than 8 million people suffer from obesity. In this context, the arrival on the market of the anti-obesity treatments Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly) represents new hope for patients. Because until now, if you were having trouble losing weight, your options were very limited. These drugs are praised by some obesity specialists for their effectiveness. Other health professionals remain cautious and point to the lack of perspective on their long-term effects.
In this video we return to the active ingredient of these new drugs, which imitate a digestive hormone produced naturally by the human body: glucagon-like peptide-1 (GLP-1). This hormone, discovered in the 1980s, acts in particular on insulin secretion and the feeling of satiety.
We also explain the conditions to benefit from this type of treatment in France, which can only be prescribed by doctors specialized in endocrinology, diabetology or nutrition. Wegogy and Mounjaro are designed to be used as a second-line treatment, after nutritional treatment has failed.
To learn more about these new treatments and the excitement they are generating in the financial markets, you will find a full analysis below.
“Understand in three minutes”
The explanatory videos that make up the “Understanding in three minutes” series are produced by the Vertical Video department of World. Broadcast mainly on platforms such as TikTok, Snapchat, Instagram and Facebook, they aim to contextualise major events in a short format and make news accessible to all.
Contribute
Reuse this content
How do Wegovy and Mounjaro compare to traditional weight loss methods like diet and exercise?
Interview between Time.news Editor and Dr. Claire Dupont, Obesity Specialist
Editor: Good afternoon, Dr. Dupont. Thank you for joining us today. The latest developments in anti-obesity treatments, specifically Wegovy and Mounjaro, have caught a lot of attention in France, especially with over 8 million people suffering from obesity. What can you tell us about these new options?
Dr. Dupont: Good afternoon! Thank you for having me. Indeed, Wegovy and Mounjaro represent significant advancements in the treatment of obesity. They utilize the active ingredient glucagon-like peptide-1 (GLP-1), which is a digestive hormone that our body naturally produces. GLP-1 plays a crucial role in stimulating insulin secretion and regulating our feelings of satiety, helping people feel fuller for longer.
Editor: That sounds promising! However, I’ve read that there is still some caution among health professionals regarding these medications. Could you elaborate on that?
Dr. Dupont: Absolutely. While these drugs have shown effectiveness, particularly as second-line treatments after dietary interventions have failed, we must proceed with caution. The long-term effects of these medications are still not fully understood, and as with any medication, there can be side effects. Therefore, it’s crucial for patients to consult with specialized doctors in endocrinology, diabetology, or nutrition before starting treatment.
Editor: So, who qualifies for these treatments in France? It sounds like there are specific criteria in place.
Dr. Dupont: Yes, indeed. In France, only patients who have struggled with diet and lifestyle changes and have not achieved significant weight loss can be considered for Wegovy or Mounjaro. This targeted approach ensures that these medications are used judiciously and that we are addressing obesity as a complex health issue rather than just a matter of willpower.
Editor: That’s a very responsible approach. With many people eagerly seeking effective solutions for obesity, do you think there is a risk of these treatments being overhyped in the media and financial markets?
Dr. Dupont: There is definitely a potential for overhype. The excitement in financial markets is driven by the effectiveness of these drugs, but it’s essential to remember that obesity is multifaceted. Treatments must be part of a comprehensive strategy that includes lifestyle changes, psychological support, and ongoing medical supervision. We cannot lose sight of the broader picture in the midst of the enthusiasm surrounding new treatments.
Editor: This holistic view is crucial. As an expert, what advice would you give to individuals who are considering these options?
Dr. Dupont: My advice would be to approach treatment from a holistic perspective. Consult with your healthcare provider to discuss the best options for you, which may include medication, but should certainly involve a commitment to lifestyle changes as well. Engage in healthy eating, physical activity, and consider psychological support if needed. Weight management is a journey, and having a comprehensive, individualized plan is key to long-term success.
Editor: Thank you for those insights, Dr. Dupont. It’s clear that while Wegovy and Mounjaro are exciting developments in obesity treatment, a balanced and informed approach is essential for effective management. We appreciate your time and expertise today.
Dr. Dupont: Thank you for having me. It’s been a pleasure discussing this important topic!
The contributions area is reserved for subscribers.
Sign up to access this discussion space and contribute to the discussion.